<DOC>
	<DOCNO>NCT02591784</DOCNO>
	<brief_summary>Nimotuzumab ( hR3 ) IgG1 humanize monoclonal antibody recognize epitope locate extra cellular domain human epidermal growth factor receptor ( EGFR ) . Clinical efficacy show adult head neck cancer . The phase II study assess efficacy safety combination Nimotuzumab administer concomitantly radiotherapy patient esophageal cancer tumour .</brief_summary>
	<brief_title>Nimotuzumab Combination With Radiotherapy Esophageal Cancer</brief_title>
	<detailed_description>Clinical efficacy show adult head neck cancer . The phase II study assess efficacy safety combination Nimotuzumab administer concomitantly radiotherapy patient esophageal cancer tumour .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1. pathologically cytology diagnose phase IIIII esophageal carcinoma IV thoracic segment carcinoma supraclavicular lymph node metastasis . 2. measureable lesion newly diagnose esophageal carcinoma . 3. age 1875 year old 4 . ECOG≤2 5 . Expect survival date ≥3 month 6. without serious disease important organ 7. signature inform consent . 1. pregnant breastfeed woman use prohibited contraceptive method . 2. psychiatric disease . 3. serious disease uncontrolled infection . 4. history tumor . 5. participation clinical trial within 1 month prior inclusion trial . 6. first antitumor treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>nimotuzumab esophageal radiotherapy</keyword>
</DOC>